Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
setmelanotide
- Development stage
- Approved
- Lead developer
- Rhythm Pharmaceuticals
- Modality
- Small Molecules, Peptides
- Administration
- Subcutaneous
01
Overview
Setmelanotide is a synthetic peptide drug that acts as an agonist of the melanocortin 4 receptor (MC4R). It is indicated for chronic weight management in patients with obesity due to rare genetic conditions affecting the MC4R pathway, specifically pro-opiomelanocortin (POMC) deficiency, proprotein convertase subtilisin/kexin type 1 (PCSK1) deficiency, leptin receptor (LEPR) deficiency, and Bardet-Biedl syndrome (BBS). Setmelanotide works by activating MC4R in the hypothalamus to reduce appetite and increase energy expenditure. Unlike some other MC4R agonists, it does not significantly increase heart rate or blood pressure. The drug was developed by Ipsen and Rhythm Pharmaceuticals and is administered as a once-daily subcutaneous injection[2][3][5][6].
- Brand names
- Imcivree
- Other names
- setmelanotide injection
02
Targets
MC4R (Melanocortin 4 receptor)
Beyond the preview
Go deeper on setmelanotide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on setmelanotide.